β-cell dysfunction and failure in type 2 diabetes: Potential mechanisms

Diabetes

Volumn 50, Issue SUPPL. 1, 2001, Pages

  Porte Jr , Daniel ^a,c   Kahn E, Steven E ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c VA SAN DIEGO HEALTHCARE SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLIN; AMYLOID; GLUCOKINASE; GLUCOSE; INSULIN; PROINSULIN;

CELL FUNCTION; CONFERENCE PAPER; HUMAN; HYPERGLYCEMIA; HYPERINSULINEMIA; IMPAIRED GLUCOSE TOLERANCE; INSULIN RELEASE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PANCREAS ISLET BETA CELL; PRIORITY JOURNAL; TRANSGENIC MOUSE;

EID: 0035125001     PISSN: 00121797     EISSN: None     Source Type: Journal    
DOI: 10.2337/diabetes.50.2007.s160     Document Type: Conference Paper

References (35)

1. Banting Lecture 1990: β-cells in type II diabetes mellitus
2. The pathophysiology of type II (noninsulin dependent) diabetes mellitus: Implications for treatment
3. Mechanisms of impaired acute insulin release in adult onset diabetes: Studies with isoproterenol and secretin
4. Insulin secretion in diabetes mellitus
5. Adaptation of B and A cell function during prolonged glucose infusion in human subjects
6. Reduction of glycemic potentiation: Sensitive indicator of β-cell loss in partially pancreatectomized dogs
7. β-cell function and insulin sensitivity in nondiabetic HLA-identical siblings of insulin-dependent diabetics
8. Defects in β-cell function and insulin sensitivity in normoglycemic streptozocin-treated baboons: A model of preclinical insulin-dependent diabetes
9. Differential volumetry of A, B, and D cells in the pancreatic islets of diabetic and nondiabetic subjects
10. Quantitative estimation of the pancreas islet tissue in diabetic subjects
11. The influence of amyloid deposits on the islet volume in maturity onset diabetes mellitus
12. Islet amyloid polypeptide-like immunoreactivity in the islet B cells of type 2 (non-insulin-dependent) diabetic and non-diabetic individuals
13. Islet amyloid polypeptide in diabetic and non-diabetic Pima Indians
14. Pancreatic expression and secretion of human islet amyloid polypeptide in a transgenic mouse
15. Chronic overproduction of islet amyloid polypeptide/amylin in transgenic mice: Lysosomal localization of human islet amyloid polypeptide and lack of marked hyperglycaemia and hyperinsulinaemia
16. Formation of islet amyloid fibrils in beta secretory granules of transgenic mice expressing human islet amyloid polypeptide/amylin
17. Human islet amyloid polypeptide transgenic mice as a model of non-insulin-dependent diabetes mellitus (NIDDM)
18. Amyloid formation in response to beta cell stress occurs in vitro, but not in vivo, in islets of transgenic mice expressing human islet amyloid polypeptide
19. Islet amyloid: A long-recognized but underappreciated pathological feature of type 2 diabetes
20. Islet amyloid formation associated with hyperglycemia in transgenic mice with pancreatic β-cell expression of human islet amyloid polypeptide
21. Extensive islet amyloid formation is induced by development of type 2 diabetes mellitus and contributes to its progression: Pathogenesis of diabetes in a mouse model
22. vy/a mice expressing human islet amyloid polypeptide
23. Pancreatic islet cell toxicity of amylin associated with type-2 diabetes mellitus
24. Defective glucose-stimulated insulin release from perifused islets of C57BL/6J mice
25. Hyperproinsulinemia and amyloid in NIDDM: Clues to etiology of islet β-cell dysfunction?
26. Sorting and processing of secretory proteins
27. Disproportionately elevated proinsulin levels reflect the degree of impaired β-cell secretory capacity in patients with non-insulin dependent diabetes mellitus
28. U.K. prospective diabetes study 16: Overview of 6 years' therapy of type II diabetes: A progressive disease
29. Assessing the potential for α-glucosidase inhibitors in prediabetic states
30. Effect of sulfonylurea withdrawal on proinsulin levels, β-cell function, and glucose disposal in subjects with non-insulin-dependent diabetes mellitus
31. Effect of sulphonylurea therapy on plasma insulin, intact and 32/33 split proinsulin in subjects with type 2 diabetes mellitus
32. Relative hyperproinsulinemia of NIDDM persists despite the reduction of hyperglycemia with insulin or sulfonylurea therapy
33. Proinsulin as a marker for the development of NIDDM in Japanese-American men
34. Longitudinal studies on the development of diabetes in individual Macaca nigra
35. A variation at position -30 of the β-cell glucokinase gene promoter is associated with reduced β-cell function in middle-aged Japanese-American men